Antithrombotic Strategy in Stroke

Summary

Numerous randomised controlled trials have been devoted to antithrombotic strategy in stroke, thus making evidence-based recommendations possible. The use of antithrombotic drugs is crucial in the treatment of ischemic stroke though often limited by the inherent risk of intra-cerebral bleeding. In the prevention of stroke, the strategy depends on the underlying etiology: (i) antiplatelet drugs (with aspirin as first choice) in atherothrombotic stroke, and (ii) oral anticoagulants in cardioembolic stroke. In the acute treatment, the strategy depends on whether IV rt-PA can be performed; if rt-PA is available and approved, its use is recommended within 3 h of the onset of symptoms provided there is strict adherence to the inclusion and exclusion criteria. In all other cases, aspirin is the treatment of choice, associated with low dose LMWH in the event of restricted mobility. There is no evidence for efficacy of high dose heparin (or LMWH) in stroke, except in cerebral venous thrombosis.

Key words

Stroke - cerebral infarction - thrombolysis - anticoagulants - antiplatelet drugs

• References

• 1 Murray Cjl, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76.
• 2 Martin J, Meltzer H, Elliot D. Office of populations, censures and surveys: surveys of disability in Great Britain report. 1 – The prevalence of disability amongst adults. London: the Stationery Office; 1988
• 3 Skoog I, Nillson L, Palmeretz B, Andreasson LA, Svanborg A. A population-based study of dementia in 85 year olds. N Engl J Med 1993; 328: 153-8.
• 4 Kotila M, Numminen H, Waltimo O, Kaste M. Depression after stroke. Results in the Finn stroke study. Stroke 1998; 29: 368-72.
• 5 Bath PMW, Lees KR. Acute stroke. Br Med J 2000; 320: 920-3.
• 6 Caplan LR. Stroke treatment. Promising but still struggling. JAMA 1998; 279: 1304-6.
• 7 Albers GW, Easton JD, Sacco RI, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998; 114: 683S-98S.
• 8 Peto R, Gray R, Collins R, Wheatley K, Hennekens CH, Jamrozik KB. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313-6.
• 9 Steering Committee of the Physicians’Health Study Research Group.. Final report on the aspirin component of the ongoing Physicians’Health Study. N Engl J Med 1989; 321: 129-35.
• 10 The Medical Research Council’s General Practice Research Framework.. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-41.
• 11 Hansson I, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D. for the HOT study goup. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
• 12 He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomised controlled trials. JAMA 1998; 280: 1930-5.
• 13 Collaborative Group of the Primary Prevention Project (PPP).. Low dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
• 14 Antiplatelet Trialists’Collaboration.. Collaborative overview of randomised trials of antiplatelet therapy. In: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
• 15 Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischemia. J Neurol Neurosurg Psychiatry 1996; 60: 197-9.
• 16 Devuyst G, Paciaroni M, Bogousslavsky J. Secondary stroke prevention: A European perspective. Cerebrovasc Dis 1999; 9 (Suppl. 03) 29-36.
• 17 Taylor DW, Barnett JHM, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE. for the ASA and carotid endarterectomy (ACE) trial collaborators. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. Lancet 1999; 353: 2179-83.
• 18 Hass WK, Easton JD, Adams Jr HP, Pryse-Phillips W, Molony BA, Anderson S. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-7.
• 19 CAPRIE steering committee.. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
• 20 Bousser MG, Eschwege E, Haguenau M, Lefauconnier JM, Thibult N, Touboul D. et al. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983; 14: 5-14.
• 21 Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R. Prévention des récidives des accidents vasculaires cérébraux ischémiques par les antiagrégants plaquettaires. Résultats d’un essai thérapeutique contrôlé de 3 ans. Rev Neurol 1982; 38: 367-85.
• 22 American Canadian Cooperative Study Group.. Persantine-aspirin trial in cerebral ischemia: endpoint results. Stroke 1985; 16: 406-15.
• 23 Diener HC, Cunha I, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
• 24 PJ Koudstaal.. Stroke prevention: which drugs to use and when?. J Neurol 1999; 246: 753-7.
• 25 Heeschen Ch, Hamm Ch W. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists. Lancet 2000; 355: 330-1.
• 26 Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-65.
• 27 Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114: 579S-89S.
• 28 Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
• 29 Petersen P, Boysen G, Godtfersen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989; 1: 175-9.
• 30 Stroke prevention in atrial fibrillation investigators.. Stroke prevention in atrial fibrillation study (SPAF): final results. Circulation 1991; 84: 527-39.
• 31 European atrial fibrillation trial study group.. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
• 32 Atrial fibrillation investigators.. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomised trials. Arch Intern Med 1997; 157: 1237-40.
• 33 Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CG. et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-12.
• 34 Stroke prevention in atrial fibrillation investigators.. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study (SPAF II). Lancet 1994; 343: 867-91.
• 35 Atrial fibrillation investigators.. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
• 36 Hart RG, Sherman DG, Easton JD, Cairns JA. Prevention of stroke in patients with non valvular atrial fibrillation. Neurology 1998; 51: 674-81.
• 37 Salem DN, Levine HJ, Pauker SG, Eckman MH, Hartnett Daudelin D. Antithrombotic therapy in valvular heart disease. Chest 1998; 114: 590S-601S.
• 38 Stein PD, Alpert JS, Dalen JE, Horstkotte D, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1998; 114: 602S-10S.
• 39 Holloway RG, Benesch C, Rush SR. Stroke prevention. Narrowing the evidence-practice gap. Neurology 2000; 54: 1899-906.
• 40 The National Institute of Neurological Disorders and Stroke rt-PA.. Stroke study group. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 1995; 333: 1581-7.
• 41 Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason C. et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Stroke 1996; 27: 1711-8.
• 42 Quality standard subcommittee of the American Academy of Neurology (AAN).. Thrombolytic therapy for acute ischemic stroke: summary statement. Neurology 1996; 47: 835-9.
• 43 Hinchey JA, Benesch C. Thrombolytic therapy in patients with acute ischemic stroke. Arch Neurol 2000; 57: 1430-6.
• 44 Verstraete M, Prentice CRM, Samama M, Verhaege R. on behalf of a European working group. A European view on the North American fifth consensus on antithrombotic therapy. Chest 2000; 117: 1755-70.
• 45 CAST (Chinese Acute Stroke Trial).. Collaborative Study Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischemic stroke. Lancet 1997; 349: 1641-9.
• 46 International Stroke Trial Study Group.. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-81.
• 47 Multicenter Acute Stroke Trial-Italy (MAST-I) group.. Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 1509-14.
• 48 Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997; 336: 847-60.
• 49 Bousser MG. Aspirin or heparin immediately after stroke?. Lancet 1997; 349: 1564-5.
• 50 The Abciximab in Ischemic stroke investigators.. A randomized, double blind, placebo-controlled, dose escalation study. Stroke 2000; 31: 601-9.
• 51 Winkley JM, Adams HP. Potential role of abciximab in ischemic cerebrovascular disease. Am J Cardiol 2000; 85: 47-51.
• 52 Bath PMW, Iddenden R, Bath FJ. Low-molecular-weight heparin and heparinoids in acute ischemic stroke. A meta-analysis of randomized controlled trials. Stroke 2000; 31: 1770-8.
• 53 The Publication Committee for the trial of ORG 10172 in acute stroke treatment (TOAST) investigators.. Low molecular weight heparinoid, ORG 10172 (dapanaroid), and outcome after acute ischemic stroke. A randomized trial. JAMA 1998; 279: 1265-72.
• 54 Berge E, Abdelnoor M, Nakstad PH, Sandset PM. on behalf of the HAEST study group. Low-molecular-weight heparin versus aspirin in patients with acute ischemic stroke and atrial fibrillation: a double-blind randomised study. Lancet 2000; 355: 1205-10.
• 55 Röden-Jullig A, Britton M. Effectiveness of heparin treatment for progressing ischaemic stroke: before and after study. J Intern Med 2000; 248: 287-91.
• 56 Chamorro A. Heparin in acute ischaemic stroke. The case for a new clinical trial. Cerebrovasc Dis 1999; 9 (Suppl. 03) 16-23.
• 57 Furlan AJ, Higashida R, Wechsler I, Schulz G. for the PROACT Investigators. PROACT-II: recombinant pro-urokinase (r-ProUK) in acute cerebral thromboembolism. Initial trial results. The PROACT-II investigators. Stroke 1999; 30: 234.
• 58 Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on fibrinolytic therapy for acute ischemic stroke. Lancet 1997; 350: 607-17.
• 59 Wardlaw JM, Yamaguchi T, Del Zoppo GJ. Thrombolysis for acute ischemic stroke (Cochrane Review). in: The Cochrane library. ed 2. Oxford Update Software 1999
• 60 Multicenter acute stroke trial-Europe (MAST-E).. Study Group: fibrinolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145-50.
• 61 Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeill JJ. et al. for the Australian streptokinase (ASK) Trial Study Group: Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996; 276: 961-6.
• 62 European Cooperative Acute Stroke Study (ECASS).. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995; 274: 1017-25.
• 63 ECASS II. Second European – Australasian Acute Stroke Study Investigators. Randomized double-blind placebo-controlled trial of fibrinolytic therapy with intravenous alteplase in acute ischemic stroke. Lancet 1998; 352: 1245-51.
• 64 Clark WM, Albers GW. for the ATLANTIS Stroke study investigators. The Atlantis rt-PA (alteplase) acute stroke trial: final results. Stroke 1999; 39: 234.
• 65 Stingele R, Bluhmki E, Hacke W. Bootstrap statistics of ECASS II data: just another post hoc analysis of a negative stroke trial?. Cerebrovasc Dis 2001; 11: 30-3.
• 66 Grotta J. Thrombolysis – The best current option for most patients. New Engl J Med 1997; 337: 1310-2.
• 67 Caplan LR, Mohr JP, Kistler JP, Koroshetz W. Thrombolysis – Not a panacea for ischemic stroke. N Engl J Med 1997; 337: 1309-10.
• 68 Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DI, Hinchey JA. et al. Use of tissue-type plasminogen activator for acute ischemic stroke. The Cleveland area experience. JAMA 2000; 283: 1151-8.
• 69 Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurru C, Biller J. Protocol violations in community-based rTPA sroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001; 32: 12-6.
• 70 Albers GW. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke 1999; 30: 2230-7.
• 71 Del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT investigators. Prolyse in acute cerebral thrombo-embolism. Stroke 1998; 29: 4-11.
• 72 Hossmann V, Heiss WD, Bewermeyer H, Wiedemann G. Controlled trial of Ancrod in ischemic stroke. Arch Neurol 1983; 40: 803-8.
• 73 Sherman DG, Arkinson RP, Chippendale T, Levin KA, Ken NG, Futrell N. et al. for the STAT participants. Intravenous Ancrod for treatment of acute ischemic stroke. The STAT study: a randomized controlled trial. JAMA 2000; 283: 2395-403.
• 74 Mayberg MR, Furlan A. Ancrod – Is snake venom an antidote for stroke?. JAMA 2000; 283: 2440-2.
• 75 Bousser MG. Cerebral venous thrombosis Nothing, heparin, or local thrombolysis?. Stroke 1999; 30: 481-3.